MedElevator Войти в исследования
← Поиск публикаций

DOI 10.4103/jcrt.jcrt_739_22

Медицинская библиотека · Journal of cancer research and therapeutics · 2023

Intrapleural nivolumab in cancer patients with pleural effusion.

Tsimafeyeu Ilya, Goutnik Vadim, Shrainer Igor, Kosyrev Vladislav, Bondarenko Anastasia, Utyashev Igor

СтатьяПеревод в очереди

Аннотация

We assessed the preliminary efficacy and toxicity of intrapleural instillation of nivolumab in patients with large pleural effusion. Patients with metastatic cancers who have a large volume of pleural effusion and required evacuation were eligible. Thoracentesis followed by nivolumab (40 mg, single intrapleural instillation) was performed. The primary endpoint was 3-month recurrence-free survival. A total of 13 patients were enrolled. The study was terminated after stage 1 as no efficacy was observed; 7 patients (54%) had a recurrence of pleural effusion at 3 months. Thirteen (100%) patients had no recurrence, dyspnea, or cough within 1 month, and the median time to recurrence was 1.9 months (95% confidence interval [CI], 1.35-2.5). No adverse events were identified. We concluded that a single intrapleural instillation of the nivolumab at 40 mg was ineffective and well-tolerated in cancer patients with pleural effusion.

Для цитирования: Tsimafeyeu Ilya, Goutnik Vadim, Shrainer Igor, Kosyrev Vladislav, Bondarenko Anastasia, Utyashev Igor. Intrapleural nivolumab in cancer patients with pleural effusion.. Journal of cancer research and therapeutics. 2023. DOI: 10.4103/jcrt.jcrt_739_22.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.